UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 29, 2025

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware13-5315170

(State of Incorporation)(I.R.S. Employer Identification No.)

66 Hudson Boulevard East, New York, New York 10001-2192

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered

Common Stock, $0.05 par valuePFENew York Stock Exchange

1.000% Notes due 2027PFE/27New York Stock Exchange

2.875% Notes due 2029

PFE/29

New York Stock Exchange

3.250% Notes due 2032

PFE/32

New York Stock Exchange

3.875% Notes due 2037

PFE/37A

New York Stock Exchange

4.250% Notes due 2045

PFE/45

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YesxNo

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

YesxNo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:

Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes Nox

At July 30, 2025, 5,685,550,500 shares of the issuer s voting common stock were outstanding.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Operations

Condensed Consolidated Statements of Comprehensive Income

Condensed Consolidated Balance Sheets

Condensed Consolidated Statements of Equity

Condensed Consolidated Statements of Cash Flows

Notes to Condensed Consolidated Financial Statements

10

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

34

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

54

Item 4.

Controls and Procedures

54

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

54

Item 1A.

Risk Factors

54

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

54

Item 3.

Defaults Upon Senior SecuritiesN/A

Item 4.

Mine Safety DisclosuresN/A

Item 5.

Other Information

54

Item 6.

Exhibits

55

Signature

55

N/A = Not Applicable

DEFINED TERMS

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 25, 2025 and May 26, 2024, and for U.S. subsidiaries is as of and for the three and six months ended June 29, 2025 and June 30, 2024. References to Notes in this Form 10-Q are to the Notes to the Condensed or Consolidated Financial Statements in this Form 10-Q or in our 2024 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined below:

Indicates calculation not meaningful or results are greater than 100%

2024 Form 10-K

Annual Report on Form 10-K for the fiscal year ended December 31, 2024

340B Program

340B Drug Pricing Program

3SBio

3SBio, Inc. and its subsidiaries Shenyang Sunshine Pharmaceutical Co., Ltd. and 3S Guojian Pharmaceutical (Shanghai) Co., Ltd.

AbbVie

AbbVie Inc.

AI

artificial intelligence

ALKanaplastic lymphoma kinase

Alliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us

AstellasAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.

ATTR-CMtransthyretin amyloid cardiomyopathy

BioNTechBioNTech SE

BiopharmaGlobal Biopharmaceuticals Business

Blackstone

Blackstone Life Sciences

BMSBristol-Myers Squibb Company

BODBoard of Directors

CDCU.S. Centers for Disease Control and Prevention

CMS

Centers for Medicare & Medicaid Services

CODMChief Operating Decision Maker

Comirnaty(a)

Unless otherwise noted, refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine; Comirnaty (COVID-19 Vaccine, mRNA) original monovalent formula; the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5); the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula); Comirnaty (COVID-19 Vaccine, mRNA) 2023-2024 Formula; Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula); Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula; Comirnaty (COVID-19 Vaccine, mRNA) 2025-2026 Formula; Comirnaty Original/Omicron BA.1; Comirnaty Original/Omicron BA.4/BA.5; Comirnaty Omicron XBB.1.5; Comirnaty JN.1 and Comirnaty KP.2.

COVID-19novel coronavirus disease of 2019

Developed MarketsIncludes, but is not limited to, the following markets: Western Europe, Japan, Central Europe, Canada, Australia, Eastern Europe, Scandinavian countries, South Korea, New Zealand and Finland

EMAEuropean Medicines Agency

Emerging MarketsIncludes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe (excluding the Balkans), Africa, the Middle East and Turkey

EPS

earnings per share

EUEuropean Union

EUAemergency use authorization

Exchange ActSecurities Exchange Act of 1934, as amended

FASBFinancial Accounting Standards Board

FDAU.S. Food and Drug Administration

Form 10-QThis Quarterly Report on Form 10-Q for the quarterly period ended June 29, 2025

GAAPU.S. Generally Accepted Accounting Principles

GSKGSK plc

HaleonHaleon plc

HIPAAHealth Insurance Portability and Accountability Act of 1996

HospiraHospira, Inc.

HRR

homologous recombination repair

IPR&Din-process research and development

IRAInflation Reduction Act of 2022

IRSU.S. Internal Revenue Service

JVjoint venture

KingKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)

mCRCmetastatic colorectal cancer

mCRPCmetastatic castration-resistant prostate cancer

mCSPCmetastatic castration-sensitive prostate cancer

MD&AManagement s Discussion and Analysis of Financial Condition and Results of Operations

MDLMulti-District Litigation

Medicare Part B

a medical insurance plan that helps cover medically necessary services, outpatient care, and preventative services for people with Medicare

Medicare Part D

a prescription drug coverage program for people with Medicare

MeridianMeridian Medical Technologies, Inc.

Moody s

Moody s Ratings (formerly Moody s Investors Service)

mRNAmessenger ribonucleic acid

NDA

New Drug Application

nmCRPCnon-metastatic castration-resistant prostate cancer

nmCSPC

non-metastatic castration-sensitive prostate cancer

NSCLCnon-small cell lung cancer

OBBBA

One Big Beautiful Bill Act

ODToral disintegrating tablet

Ono

Ono Pharmaceutical Co., Ltd.

OTCover-the-counter

Paxlovid(a)

an oral COVID-19 treatment (nirmatrelvir tablets and ritonavir tablets)

PC1Pfizer CentreOne

PharmaciaPharmacia LLC (formerly Pharmacia Corporation)

Pierre Fabre

Pierre Fabre Medicament SAS

PNIF

Pfizer Netherlands International Finance B.V. (a wholly-owned finance subsidiary of Pfizer)

Prevnar familyIncludes Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult)

PsApsoriatic arthritis

QTDQuarter-to-date or three months ended

RArheumatoid arthritis

R&Dresearch and development

RSVrespiratory syncytial virus

S&PS&P Global (formerly Standard & Poor s)

SeagenSeagen Inc. and its subsidiaries

SECU.S. Securities and Exchange Commission

SI&A

Selling, informational and administrative expenses

Takeda

Takeda Pharmaceutical Company Limited

UCulcerative colitis

U.K.United Kingdom

U.S.United States

ViiVViiV Healthcare Limited

Vyndaqel familyIncludes Vyndaqel, Vyndamax and Vynmac

YTDYear-to-date or six months ended

(a)Certain uses of Paxlovid and COVID-19 vaccines from BioNTech and Pfizer have not been approved or licensed by the FDA. Paxlovid has been authorized for emergency use by the FDA under an EUA for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. Emergency uses of COVID-19 vaccines from Pfizer and BioNTech, including Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula), have been authorized for emergency use by the FDA under an EUA to prevent COVID-19 in individuals aged 6 months of age and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the COVID-19 pandemic under Section 564(b)(1) of the U.S. Federal Food, Drug and Cosmetics Act, unless the declaration is terminated or authorization revoked sooner. Please see the EUA Fact Sheets at www.covid19oralrx.com and www.cvdvaccine-us.com.

This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or efficacy of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.

Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.

The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our X (formerly known as Twitter) accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.

Certain of the products and product candidates discussed in this Form 10-Q are being co-researched, co-developed and/or co-promoted in collaboration with other companies for which Pfizer s rights vary by market or are the subject of agreements pursuant to which Pfizer has commercialization rights in certain markets.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

Three Months EndedSix Months Ended

(MILLIONS, EXCEPT PER SHARE DATA)June 29,

2025June 30,

2024June 29,

2025June 30,

2024

Revenues:

Product revenues

$11,954 $10,871 $23,248 $23,314

Alliance revenues

2,273 2,067 4,386 4,240

Royalty revenues

426 345 734 608

Total revenues14,653 13,283 28,367 28,162

Costs and expenses:

Cost of sales(a)

3,778 3,300 6,624 6,679

Selling, informational and administrative expenses(a)

3,415 3,717 6,446 7,212

Research and development expenses(a)

2,482 2,696 4,685 5,189

Acquired in-process research and development expenses2 6 11 6

Amortization of intangible assets1,211 1,307 2,421 2,615

Restructuring charges and certain acquisition-related costs(18)1,254 660 1,356

Other (income)/deductions net739 1,107 1,692 1,787

Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)

3,044 (103)5,828 3,318

Provision/(benefit) for taxes on income/(loss)

141 (134)(48)159

Income from continuing operations2,903 31 5,876 3,159

Discontinued operations net of tax25 17 25 12

Net income before allocation to noncontrolling interests

2,928 48 5,901 3,171

Less: Net income attributable to noncontrolling interests18 7 24 15

Net income attributable to Pfizer Inc. common shareholders

$2,910 $41 $5,877 $3,156

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders

$0.51 $0.01 $1.03 $0.56

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

$0.51 $0.01 $1.03 $0.56

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders

$0.51 $0.01 $1.03 $0.55

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

$0.51 $0.01 $1.03 $0.55

Weighted-average shares basic5,685 5,666 5,680 5,662

Weighted-average shares diluted5,706 5,696 5,708 5,696

(a)Exclusive of amortization of intangible assets.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months EndedSix Months Ended

(MILLIONS)June 29,

2025June 30,

2024June 29,

2025June 30,

2024

Net income before allocation to noncontrolling interests$2,928 $48 $5,901 $3,171

Foreign currency translation adjustments, net127 (70)(430)70

Unrealized holding gains/(losses) on derivative financial instruments, net(273)127 (395)343

Reclassification adjustments for (gains)/losses included in net income(a)

(106)(147)(419)(159)

(379)(21)(814)184

Unrealized holding gains/(losses) on available-for-sale securities, net166 (25)135 (77)

Reclassification adjustments for (gains)/losses included in net income(b)

(83)100 72 86

82 74 207 9

Reclassification adjustments related to amortization of prior service costs and other, net(24)(28)(55)(56)

Reclassification adjustments related to curtailments of prior service costs and other, net(11) (44)

(35)(28)(99)(56)

Other comprehensive income/(loss), before tax(204)(44)(1,136)207

Tax provision/(benefit) on other comprehensive income/(loss)(347)22 (538)76

Other comprehensive income/(loss) before allocation to noncontrolling interests$143 $(67)$(598)$131

Comprehensive income/(loss) before allocation to noncontrolling interests$3,071 $(19)$5,303 $3,302

Less: Comprehensive income/(loss) attributable to noncontrolling interests18 (2)22 1

Comprehensive income/(loss) attributable to Pfizer Inc.$3,053 $(17)$5,282 $3,302

(a)Reclassified into Other (income)/deductions net and Cost of sales. See Note 7E.

(b)Reclassified into Other (income)/deductions net.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS)June 29,

2025December 31, 2024

(Unaudited)

Assets

Cash and cash equivalents$1,638 $1,043

Short-term investments11,611 19,434

Trade accounts receivable, net of allowance for doubtful accounts: 2025 $439; 2024 $438

12,078 11,463

Inventories11,669 10,851

Current tax assets4,016 3,314

Other current assets2,690 4,253

Total current assets43,703 50,358

Equity-method investments224 217

Long-term investments1,896 2,010

Property, plant and equipment, net of accumulated depreciation: 2025 $17,268; 2024 $16,483

18,776 18,393

Identifiable intangible assets, net

52,702 55,411

Goodwill68,997 68,527

Noncurrent deferred tax assets and other noncurrent tax assets10,343 8,662

Other noncurrent assets9,455 9,817

Total assets$206,095 $213,396

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2025 $4,246; 2024 $3,747

$4,295 $6,946

Trade accounts payable5,166 5,633

Dividends payable2,445 2,437

Income taxes payable3,675 2,910

Accrued compensation and related items2,447 3,838

Deferred revenues1,123 1,511

Other current liabilities18,575 19,720

Total current liabilities37,726 42,995

Long-term debt57,502 57,405

Pension and postretirement benefit obligations2,130 2,115

Noncurrent deferred tax liabilities2,481 2,122

Other taxes payable3,313 6,112

Other noncurrent liabilities13,931 14,150

Total liabilities117,083 124,899

Commitments and Contingencies

Common stock481 480

Additional paid-in capital94,053 93,603

Treasury stock(115,010)(114,763)

Retained earnings117,609 116,725

Accumulated other comprehensive loss(8,438)(7,842)

Total Pfizer Inc. shareholders equity88,695 88,203

Equity attributable to noncontrolling interests317 294

Total equity89,012 88,497

Total liabilities and equity$206,095 $213,396

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(UNAUDITED)

PFIZER INC. SHAREHOLDERS

Common StockTreasury Stock

(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, March 31, 20259,620 $481 $93,856 (3,935)$(115,008)$119,590 $(8,581)$90,338 $299 $90,637

Net income/(loss)

2,910 2,910 18 2,928

Other comprehensive income/(loss), net of tax

143 143 143

Cash dividends declared, per share: $0.86

Common stock(4,890)(4,890)(4,890)

Share-based payment transactions 197 (2)(1)195 195

Other (1)(1) (1)

Balance, June 29, 20259,620 $481 $94,053 (3,935)$(115,010)$117,609 $(8,438)$88,695 $317 $89,012

PFIZER INC. SHAREHOLDERS

Common StockTreasury Stock

(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, March 31, 20249,592 $480 $92,997 (3,925)$(114,755)$121,318 $(7,758)$92,282 $276 $92,558

Net income/(loss)

41 41 7 48

Other comprehensive income/(loss), net of tax(58)(58)(9)(67)

Cash dividends declared, per share: $0.84

Common stock (4,760)(4,760)(4,760)

Share-based payment transactions 200 (2)(2)196 196

Other

Balance, June 30, 20249,592 $480 $93,197 (3,925)$(114,757)$116,596 $(7,816)$87,700 $275 $87,975

PFIZER INC. SHAREHOLDERS

Common StockTreasury Stock

(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, January 1, 20259,593 $480 $93,603 (3,926)$(114,763)$116,725 $(7,842)$88,203 $294 $88,497

Net income

5,877 5,877 24 5,901

Other comprehensive income/(loss), net of tax(596)(596)(3)(598)

Cash dividends declared, per share: $0.86

Common stock(4,890)(4,890)(4,890)

Share-based payment transactions28 1 450 (9)(246)(104)101 101

Other 2 2

Balance, June 29, 20259,620 $481 $94,053 (3,935)$(115,010)$117,609 $(8,438)$88,695 $317 $89,012

PFIZER INC. SHAREHOLDERS

Common StockTreasury Stock

(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, January 1, 20249,562 $478 $92,631 (3,916)$(114,487)$118,353 $(7,961)$89,014 $274 $89,288

Net income

3,156 3,156 15 3,171

Other comprehensive income/(loss), net of tax145 145 (14)131

Cash dividends declared, per share: $0.84

Common stock (4,760)(4,760)(4,760)

Share-based payment transactions30 1 566 (10)(270)(153)144 144

Other

Balance, June 30, 20249,592 $480 $93,197 (3,925)$(114,757)$116,596 $(7,816)$87,700 $275 $87,975

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Six Months Ended

(MILLIONS)June 29,

2025June 30,

2024

Operating Activities

Net income before allocation to noncontrolling interests$5,901 $3,171

Discontinued operations net of tax25 12

Net income from continuing operations before allocation to noncontrolling interests5,876 3,159

Adjustments to reconcile net income from continuing operations before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:

Depreciation and amortization3,243 3,467

Asset write-offs and impairments498 431

Deferred taxes(935)(1,224)

Share-based compensation expense373 426

Benefit plan contributions in excess of expense/income(334)(338)

Other adjustments, net(61)260

Other changes in assets and liabilities, net of acquisitions and divestitures(6,908)(6,871)

Net cash provided by/(used in) operating activities1,753 (691)

Investing Activities

Purchases of property, plant and equipment(1,182)(1,341)

Purchases of short-term investments(6,085)(1,254)

Proceeds from redemptions/sales of short-term investments10,500 1,712

Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less(2,668)3,538

Purchases of long-term investments(86)(108)

Proceeds from redemptions/sales of long-term investments145 312

Proceeds from sales of investment in Haleon(a)

6,311 3,491

Other investing activities, net288 (18)

Net cash provided by/(used in) investing activities7,225 6,332

Financing Activities

Proceeds from short-term borrowings 6,014

Payments on short-term borrowings(2,199)(4,852)

Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less

(903)(1,101)

Proceeds from issuance of long-term debt3,687

Payments on long-term debt(3,750)(2,250)

Cash dividends paid(4,882)(4,752)

Other financing activities, net(377)(449)

Net cash provided by/(used in) financing activities(8,423)(7,390)

Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents

34 (46)

Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents588 (1,794)

Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period1,107 2,917

Cash and cash equivalents and restricted cash and cash equivalents, at end of period$1,694 $1,123

Supplemental Cash Flow Information

Cash paid/(received) during the period for:

Income taxes

$3,493 $2,686

Interest paid

1,483 1,553

Interest rate hedges29 (2)

(a) See Note 7A.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2024 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.

These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2024 Form 10-K. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 25, 2025 and May 26, 2024, and for U.S. subsidiaries is as of and for the three and six months ended June 29, 2025 and June 30, 2024.

We manage our commercial operations through three operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite. Biopharma is the only reportable segment. See Note 13A.

B. Revenues and Trade Accounts Receivable

Deductions from Revenues Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:

(MILLIONS)June 29,

2025December 31, 2024

Reserve against Trade accounts receivable, net of allowance for doubtful accounts

$1,589 $1,627

Other current liabilities:

Accrued rebates8,692 7,195

Other accruals644 972

Other noncurrent liabilities

742 1,029

Total accrued rebates and other sales-related accruals$11,667 $10,822

Trade Accounts Receivable Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.

In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded.

During the three and six months ended June 29, 2025 and June 30, 2024, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see Note 1G in our 2024 Form 10-K.

Note 2. Research and Development Arrangement

Research and Development Funding Arrangement with Blackstone In March 2025, we entered into an arrangement with Blackstone under which we will receive up to a total of $326 million in 2025 through 2028 to co-fund our quarterly development costs for specified treatments. As there is substantive transfer of risk to the financial partner, the development funding is recognized by us as an obligation to perform contractual services. We are recognizing the funding as a reduction of Research and development expenses using an attribution model over the period of the related expenses. If successful, upon regulatory approval in the U.S. or certain major markets in the EU for the indications based on the applicable clinical trials, Blackstone will be eligible to receive approval-based fixed milestone payments of up to $277 million contingent upon the successful results of the clinical trials and payable to Blackstone over a period of one to three years. Following potential regulatory approval, Blackstone will be eligible to receive a combination of fixed milestone payments of up to $897 million in

10

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

total based on achievement of certain levels of cumulative applicable net sales and payable to Blackstone over a period of five to seven years. The net present value of the approval-based milestone payments and sales-based milestone payments will be recorded as intangible assets and amortized to Amortization of intangible assets over the shorter of the term of the agreement or estimated commercial life of the product. Accretion of interest on the liabilities to pay Blackstone will be recognized as interest expense in Other (income)/deductions net.

Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

A. Realigning Our Cost Base Program

In the fourth quarter of 2023, we announced that we launched a multi-year, enterprise-wide cost realignment program that aims to realign our costs with our longer-term revenue expectations. We expect costs associated with this initial part of the program to continue primarily through 2025 and to total approximately $3.1 billion, primarily representing cash expenditures for severance, exit and implementation costs as well as non-cash asset write downs of which $2.4 billion is associated with our Biopharma segment.

In the second quarter of 2025, we identified additional productivity opportunities to further reduce costs primarily in SI&A, driven in large part by enhanced digital enablement, including automation and AI, and simplification of business processes. We expect costs associated with the additional productivity opportunities to be incurred through 2027 and to total approximately $1.6 billion, primarily representing cash expenditures for severance, digital enablement and implementation, of which $700 million is associated with our Biopharma segment.

In connection with our efforts to simplify the structure and sharpen the focus of our R&D organization, in the first quarter of 2025, we expanded this program after having identified additional opportunities to drive improvements in productivity and operational efficiencies through enhanced digital enablement, including automation and AI, and simplification of business processes. We expect costs to implement these initiatives to be incurred through 2026 and to total approximately $600 million, primarily representing cash expenditures for severance, digital enablement and implementation, all of which is associated with our Biopharma segment. The majority of these costs were recorded in the first quarter of 2025, with cash outlays expected primarily in 2025 and 2026.

We expect costs associated with all three components of this program to total approximately $5.3 billion of which $3.7 billion is associated with the Biopharma segment.

From the start of this program through June 29, 2025, we incurred total costs under this program of $3.5 billion, of which $2.7 billion is associated with our Biopharma segment (including $2.5 billion of restructuring charges).

B. Manufacturing Optimization Program

In the second quarter of 2024, we announced that we launched a multi-year, multi-phased program to reduce our costs of goods sold, which is expected to include operational efficiencies, network structure changes, and product portfolio enhancements. The first phase of this program is focused on operational efficiencies, and we expect costs for this first phase to total approximately $1.4 billion, primarily representing cash expenditures for severance and implementation costs, all of which is associated with our Biopharma segment. From the start of this program through June 29, 2025, we incurred costs under this program of $850 million, substantially all of which is restructuring costs for our Biopharma segment. These costs were recorded primarily in 2024, with cash outlays expected primarily in 2025 and 2026.

11

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

C. Key Activities

The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:

Three Months EndedSix Months Ended

(MILLIONS)June 29,

2025June 30,

2024June 29,

2025June 30,

2024

Restructuring charges/(credits):

Employee terminations$(148)$1,014 $236 $984

Asset impairments44 41 217 66

Exit costs

30 49 94 63

Restructuring charges/(credits)(a)

(74)1,104 547 1,114

Transaction costs(b)

Integration costs and other(c)

56 150 113 237

Restructuring charges and certain acquisition-related costs(18)1,254 660 1,356

Net periodic benefit costs/(credits) recorded in Other (income)/deductions net

(9)2 (68)5

Additional depreciation asset restructuring recorded in our condensed consolidated statements of operations as follows(d):

Cost of sales3 1 7 5

Selling, informational and administrative expenses 3 3

Total additional depreciation asset restructuring

4 4 7 8

Implementation costs recorded in our condensed consolidated statements of operations as follows(e):

Cost of sales26 49 46 65

Selling, informational and administrative expenses14 36 20 65

Research and development expenses39 20 62 33

Total implementation costs78 105 128 163

Total costs associated with acquisitions and cost-reduction/productivity initiatives$54 $1,364 $727 $1,532

(a)Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) credits of $406 million for the three months ended June 29, 2025 (including credits of $408 million for our Manufacturing Optimization Program and $25 million for our Realigning our Cost Base Program), (ii) charges of $211 million for the six months ended June 29, 2025 (including charges of $562 million for our Realigning our Cost Base Program and credits of $412 million for our Manufacturing Optimization Program) and (iii) charges of $1.1 billion for both the three and six months ended June 30, 2024 (including charges of $1.3 billion for our Manufacturing Optimization Program for both periods presented and credits of $113 million for the three months and $199 million for the six months ended June 30, 2024 for our Realigning our Cost Base Program). For all periods presented, Employee terminations include revisions of estimates of previously recorded accruals for severance benefits, driven in large part by higher-than-expected voluntary attrition.

(b)Represents external costs for banking, legal, accounting and other similar services.

(c)Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.

(d)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.

(e)Represents incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

The following summarizes the components and changes in restructuring accruals:

(MILLIONS)Employee

Termination

CostsAsset

Impairment

ChargesExit CostsAccrual

Balance, December 31, 2024(a)

$2,046 $ $74 $2,120

Provision

236 217 94 547

Utilization and other(b)

(494)(217)30 (681)

Balance, June 29, 2025(c)

$1,788 $ $198 $1,986

(a)Included in Other current liabilities ($1.7 billion) and Other noncurrent liabilities ($437 million).

(b)Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.

(c)Included in Other current liabilities ($1.3 billion) and Other noncurrent liabilities ($685 million).

12

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 4. Other (Income)/Deductions Net

Components of Other (income)/deductions net include:

Three Months EndedSix Months Ended

(MILLIONS)June 29,

2025June 30,

2024June 29,

2025June 30,

2024

Interest income$(156)$(130)$(299)$(259)

Interest expense654 778 1,308 1,568

Net interest expense(a)

498 648 1,009 1,310

Net (gains)/losses recognized during the period on equity securities(b)

(75)342 295 317

Net periodic benefit costs/(credits) other than service costs(101)(106)(260)(209)

Certain legal matters, net(c)

422 169 564 377

Certain asset impairments(d)

93 240 317 349

Haleon equity method (income)/loss

(40) 48

Other, net(e)

(97)(146)(233)(404)

Other (income)/deductions net$739 $1,107 $1,692 $1,787

(a)The decrease in net interest expense in the second quarter and first six months of 2025 reflects (i) a decrease in interest expense primarily driven by a reduction in commercial paper outstanding and (ii) an increase in interest income due to higher total average investment asset balance compared to 2024.

(b)The net losses in the first six months of 2025 include, among other things, a net loss of $144 million related to our investment in Haleon, composed of unrealized losses of $1.0 billion, partially offset by $900 million in realized gains on the sales of our remaining investment.

(c)The amounts for the second quarter and first six months of 2025 primarily include certain product liability and other legal expenses. The amounts for the second quarter and first six months of 2024 primarily included certain product liability expenses related to products discontinued and/or divested by Pfizer.

(d)The first six months of 2025 primarily includes an intangible asset impairment charge associated with our Biopharma segment of $210 million for KRAS G12D, a Phase 2 indefinite-lived out-licensed asset that was discontinued by our out-licensing partner. The amounts for the second quarter and first six months of 2024 included a $240 million intangible asset impairment charge, associated with our Biopharma segment that represented IPR&D related to a Phase 3 study for the treatment of DMD, which reflected unfavorable clinical trial results.

(e)The first six months of 2025 primarily include dividend income of $111 million from our investment in ViiV. The first six months of 2024 included, among other things, a $150 million realized gain on the partial sale of our investment in Haleon and dividend income of $135 million from our investment in ViiV.

Additional information about the intangible assets that were impaired during 2025 follows:

Six Months Ended

Fair Value(a)

June 29, 2025

(MILLIONS)AmountLevel 1Level 2Level 3Impairment

Indefinite-lived licensing agreement(b)

$ $ $ $ $210

IPR&D(b), (c)

590 590 93

Developed technology rights(b)

14

Total

$590 $ $ $590 $317

(a)The fair value amount is presented as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See Note 1E in our 2024 Form 10-K.

(b)Reflects intangible assets written down to fair value in 2025. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

(c)See Note 9.

Note 5. Tax Matters

A. Taxes on Income/(Loss) from Continuing Operations

Our effective tax rate for continuing operations was 4.6% for the second quarter of 2025, compared to 130.2% for the second quarter of 2024, and was (0.8)% for the first six months of 2025, compared to 4.8% for the first six months of 2024. The lower effective tax rate for the second quarter of 2025, compared to the second quarter of 2024, was primarily due to a favorable change in the jurisdictional mix of earnings. The negative and lower effective tax rate for the first six months of 2025, compared to the first six months of 2024, was primarily due to tax benefits related to global income tax resolutions in multiple tax jurisdictions spanning multiple tax years.

13

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings (Transition Tax liability) over eight years through 2026. The seventh annual installment was paid by its April 15, 2025 due date. The eighth and final annual installment is due April 15, 2026 and is reported in current Income taxes payable as of June 29, 2025. Our obligations may vary due to the availability of attributes such as foreign tax and other credit carryforwards or carrybacks.

See Note 5A in our 2024 Form 10-K for information on our cash paid for income taxes, net of refunds.

B. Tax Contingencies

We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.

The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. Tax years 2019-2022 are under audit. Tax years 2023-2025 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years and certain related audits, appeals and investigations in certain major international tax jurisdictions dating back to 2014.

See Note 5D in our 2024 Form 10-K.

C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)

Components of Tax provision/(benefit) on other comprehensive income/(loss) include:

Three Months EndedSix Months Ended

(MILLIONS)June 29,

2025June 30,

2024June 29,

2025June 30,

2024

Foreign currency translation adjustments, net(a)

$(269)$18 $(372)$42

Unrealized holding gains/(losses) on derivative financial instruments, net(48)26 (82)70

Reclassification adjustments for (gains)/losses included in net income

(32)(23)(87)(26)

(80)3 (169)44

Unrealized holding gains/(losses) on available-for-sale securities, net21 (3)17 (9)

Reclassification adjustments for (gains)/losses included in net income

(10)12 9 11

10 9 26 1

Reclassification adjustments related to amortization of prior service costs and other, net(6)(9)(13)(13)

Reclassification adjustments related to curtailments of prior service costs and other, net(1)1 (10)1

(7)(7)(23)(12)

Tax provision/(benefit) on other comprehensive income/(loss)$(347)$22 $(538)$76

(a)Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.

Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests

The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:

Net Unrealized Gains/(Losses)Benefit Plans

(MILLIONS)Foreign Currency Translation Adjustments(a)

Derivative Financial InstrumentsAvailable-For-Sale SecuritiesPrior Service (Costs)/Credits and OtherAccumulated Other Comprehensive Income/(Loss)

Balance, January 1, 2025

$(7,984)$57 $(106)$191 $(7,842)

Other comprehensive income/(loss)(b)

(56)(645)181 (76)(596)

Balance, June 29, 2025$(8,040)$(589)$75 $115 $(8,438)

(a)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests.

(b)Foreign currency translation adjustments include net gains/(losses) related to the impact of our net investment hedging program.

14

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 7. Financial Instruments

A. Fair Value Measurements

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:

June 29, 2025December 31, 2024

(MILLIONS)TotalLevel 1Level 2TotalLevel 1Level 2

Financial assets:

Short-term investments

Equity securities with readily determinable fair value(a)

$1,687 $ $1,687 $7,848 $6,456 $1,392

Available-for-sale debt securities:

Government and agency non-U.S.

5,640 5,640 6,855 6,855

Government and agency U.S.

2,290 2,290 2,853 2,853

Corporate and other

1,595 1,595 1,173 1,173

9,525 9,525 10,881 10,881

Total short-term investments11,212 11,212 18,729 6,456 12,273

Other current assets

Derivative assets:

Foreign exchange contracts

281 281 1,056 1,056

Total other current assets281 281 1,056 1,056

Long-term investments

Equity securities with readily determinable fair values(b)

1,118 1,118 1,246 1,246

Available-for-sale debt securities:

Government and agency non-U.S.

1 1

1 1

Total long-term investments1,119 1,118 1 1,246 1,246

Other noncurrent assets

Derivative assets:

Interest rate contracts

59 59 13 13

Foreign exchange contracts

27 27 447 447

Total derivative assets86 86 460 460

Insurance contracts(c)

923 923 875 875

Total other noncurrent assets1,009 1,009 1,335 1,335

Total assets$13,621 $1,118 $12,503 $22,366 $7,701 $14,665

Financial liabilities:

Other current liabilities

Derivative liabilities:

Interest rate contracts$18 $ $18 $28 $ $28

Foreign exchange contracts

681 681 217 217

Total other current liabilities698 698 245 245

Other noncurrent liabilities

Derivative liabilities:

Interest rate contracts229 229 397 397

Foreign exchange contracts

984 984 723 723

Total other noncurrent liabilities1,213 1,213 1,121 1,121

Total liabilities$1,911 $ $1,911 $1,366 $ $1,366

(a)Includes money market funds primarily invested in U.S. Treasury and government debt. As of December 31, 2024, short-term equity securities included our investment in Haleon of $6.5 billion. In the first quarter of 2025, we sold the remaining portion of our investment in Haleon for $6.3 billion.

(b)Long-term equity securities of $131 million as of June 29, 2025 and $133 million as of December 31, 2024 were held in restricted trusts for U.S. non-qualified employee benefit plans.

(c)Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions net (see Note 4).

Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The carrying value of Long-term debt, excluding the current portion, was $58 billion as of June 29, 2025 and $57 billion as of December 31, 2024. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $55 billion as of June 29, 2025 and $54 billion as of December 31, 2024.

The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of June 29, 2025 and December 31, 2024. The fair value measurements of our held-to-maturity debt securities and short-term

15

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.

B. Investments

Total Short-Term, Long-Term and Equity-Method Investments

The following summarizes our investments by classification type:

(MILLIONS)June 29,

2025 December 31, 2024

Short-term investments

Equity securities with readily determinable fair values

$1,687 $7,848

Available-for-sale debt securities9,525 10,881

Held-to-maturity debt securities399 705

Total Short-term investments$11,611 $19,434

Long-term investments

Equity securities with readily determinable fair values(a)

$1,118 $1,246

Available-for-sale debt securities1

Held-to-maturity debt securities48 45

Private equity securities at cost(a)

729 719

Total Long-term investments$1,896 $2,010

Equity-method investments224 217

Total long-term investments and equity-method investments$2,120 $2,228

Held-to-maturity cash equivalents$390 $184

(a)Represent investments in the life sciences sector.

Debt Securities

Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:

June 29, 2025December 31, 2024

Gross Unrealized Maturities (in Years)

Gross Unrealized

(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1

to 5Over 5Amortized CostGainsLossesFair Value

Available-for-sale debt securities

Government and agency non-U.S.

$5,556 $85 $(1)$5,640 $5,640 $1 $ $6,970 $8 $(123)$6,855

Government and agency U.S.

2,290 2,290 2,290 2,853 2,853

Corporate and other1,593 2 1,595 1,595 1,179 (6)1,173

Held-to-maturity debt securities

Time deposits and other

832 832 789 9 34 697 697

Government and agency non-U.S.

5 5 5 237 237

Total debt securities$10,276 $87 $(1)$10,362 $10,314 $14 $34 $11,935 $8 $(129)$11,814

Any expected credit losses to these portfolios would be immaterial to our financial statements.

Equity Securities

The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:

Three Months EndedSix Months Ended

(MILLIONS)June 29,

2025June 30,

2024June 29,

2025June 30,

2024

Net (gains)/losses recognized during the period on equity securities(a)

$(75)$342 $295 $317

Less: Net (gains)/losses recognized during the period on equity securities sold during the period(10)(2)(934)(216)

Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date(b)

$(65)$344 $1,230 $533

(a)Reported in Other (income)/deductions net. See Note 4.

16

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(b)Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of June 29, 2025, there were cumulative impairments and downward adjustments of $435 million and upward adjustments of $239 million. Impairments, downward and upward adjustments were not material to our operations in the second quarters and first six months of 2025 and 2024.

C. Short-Term Borrowings

Short-term borrowings include:

(MILLIONS) June 29,

2025 December 31, 2024

Commercial paper, principal amount

$ $2,453

Current portion of long-term debt, principal amount4,250 3,750

Other short-term borrowings, principal amount(a)

50 755

Total short-term borrowings, principal amount

4,300 6,957

Net unamortized discounts, premiums and debt issuance costs(4)(12)

Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted